Skip to main content

Recursion Pharmaceuticals, Inc. (RXRX) Stock

Recursion Pharmaceuticals, Inc. Stock Details, Movements and Public Alerts

Stock Details

Recursion Pharmaceuticals, Inc. (RXRX), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $3.32. Over the past 52 weeks, it has ranged between $2.77 and $7.18. This places the current price at 46.2% of its 52-week high and 19.9% above its 52-week low. Recent trading volume was recorded at 10,644,052. The 14-day Relative Strength Index (RSI) stands at 53.10, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $3.30 by 0.61%. Similarly, it is below its 200-day moving average of $3.79 by 12.40%. The MACD histogram is 0.04, indicating bullish momentum0. There is currently 1 active alert set for RXRX by users.

52-Week Range

$7.18 - $2.77

-53.76% from high · +19.86% from low

Avg Daily Volume

17,438,443

20-day average

100-day avg: 17,687,292

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-3.72

Price to Book

1.92

EV/EBITDA

-2.72

EPS (TTM)

-$0.98

Price to Sales

32.16

Beta

1.05

Similar volatility to market

Q:How is RXRX valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is RXRX's risk profile compared to the market?
With a beta of 1.05, Recursion Pharmaceuticals, Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 1.92 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-1759.69%

EBITDA

$-471,604,000

Return on Equity

-56.58%

Return on Assets

-27.33%

Revenue Growth (YoY)

-60.10%

Q:How profitable and efficient is RXRX's business model?
0 The operating margin of -1759.69% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -56.58% and ROA at -27.33%, the company achieves moderate returns on invested capital.
Q:What are RXRX's recent growth trends?
Recursion Pharmaceuticals, Inc.'s revenue declined by 60.10% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$1.8B

Revenue (TTM)

$54.86M

Revenue/Share (TTM)

$0.11

Shares Outstanding

535.34M

Book Value/Share

$1.71

Asset Type

EQUITY

Q:What is RXRX's market capitalization and position?
Recursion Pharmaceuticals, Inc. has a market capitalization of $1.8B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 535.34M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does RXRX's price compare to its book value?
Recursion Pharmaceuticals, Inc.'s book value per share is $1.71, while the current stock price is $3.32, resulting in a price-to-book (P/B) ratio of 1.94. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$7.25

118.37% upside potential

Analyst Recommendations

Strong Buy

2

Buy

1

Hold

5

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for RXRX?
8 analysts cover RXRX with 38% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $7.25 implies 118.4% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on RXRX?
Current analyst recommendations:2 Strong Buy, 1 Buy, 5 Hold, 00The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 13, 2026, 02:06 AM

Technical Indicators

RSI (14-day)

53.10

Neutral

50-Day Moving Average

$3.30

0.61% above MA-50

200-Day Moving Average

$3.79

-12.40% below MA-200

MACD Line

N/A

MACD Signal

-0.04

MACD Histogram

0.04

Bullish

Q:What does RXRX's RSI value tell investors?
The RSI (Relative Strength Index) for RXRX is currently 53.10, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret RXRX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.00 above the signal line at -0.04, with histogram at 0.04. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($3.30) is below the 200-day MA ($3.79), forming a death cross pattern that often warns of extended weakness. Price is currently between the MAs, suggesting transition.

Indicators last updated: Aug 13, 2026, 01:19 AM

Active Alerts

Alert Condition
Golden Cross
Threshold
N/A
Created
Dec 31, 2025, 05:16 AM

Stay Ahead of the Market with Recursion Pharmaceuticals, Inc. Alerts

Set up price alerts for Recursion Pharmaceuticals, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.